Skip to main content

Notice for nelarabine (Reach Pharmaceuticals Pty Ltd)

Active ingredients
nelarabine
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Solution for infusion
Indication
Treatment of patients with t-cell acute lymphoblastic leukemia and t-cell lymphoblastic lymphoma
Therapeutic area
Haematology

Help us improve the Therapeutic Goods Administration site